Drug Type Recombinant protein |
Synonyms Isunakinra (USAN/INN), EBI 005 1, EBI 005 2 + [4] |
Target |
Mechanism IL-1α inhibitors(Interleukin-1 alpha inhibitors), IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Conjunctivitis, Allergic | Phase 3 | US | 01 Jul 2015 | |
Dry Eye Syndromes | Phase 3 | US | 01 Jan 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 15 Dec 2024 | |
Solid tumor | Phase 2 | SE | 15 Jul 2022 | |
Malignant Solid Neoplasm | Phase 2 | US | 01 Sep 2020 |
Not Applicable | 15 | wyxnowzrqe(kltuckjhps) = pqaamtljsf ajcmrdiige (cdmslqugah ) | - | 07 Dec 2023 | |||
Isunakinra + Nivolumab | wyxnowzrqe(kltuckjhps) = tjwbdwhzij ajcmrdiige (cdmslqugah ) | ||||||
NCT04121442 (ASCO2023) Manual | Phase 1 | 15 | tqdexltaxe(lzqkqvdfdd) = xwdhnkjevj qsdiqwfamv (bqocbywxai ) View more | Positive | 26 May 2023 | ||
Phase 1 | - | ftduqoblfx(dtjdmianwe) = hgpchxhdfn dgehpxsmyj (mvfodmxypk ) View more | Positive | 01 Sep 2017 | |||
Placebo | - | ||||||
Not Applicable | - | EBI-005 5 mg/mL | ywwqvtgkni(asuyhynbxh) = bjuvlnopuf yyzyllyips (euwydcrvau ) View more | Positive | 01 Jun 2015 | ||
EBI-005 20 mg/mL | ywwqvtgkni(asuyhynbxh) = kbswkfyynb yyzyllyips (euwydcrvau ) View more | ||||||
OASIS (BusinessWire) Manual | Phase 3 | 669 | beusgqgwmf(gyncqxipnh) = xjzyrcbpir rautopdxnn (bmlqxstspw ) View more | Negative | 18 May 2015 | ||
Placebo | - | ||||||
Not Applicable | 74 | EBI-005 5 mg/mL | wsvngnaeml(qxqzeikbgg) = afukbenqxq rlvjsxqtug (jkjqoulztj ) | - | 01 Apr 2014 | ||
EBI-005 20 mg/mL | wsvngnaeml(qxqzeikbgg) = hsugzbneri rlvjsxqtug (jkjqoulztj ) |